While Wall Street frowned on Labopharm Inc.'s decision to conduct another Phase III trial of its once-daily formulation of tramadol, the company's president and CEO reiterated what one analyst said on a conference call Wednesday. (BioWorld Today)

It may be true that “two out of three ain’t bad” - but two pieces of good news and one seriously negative item added up to trouble on Wall Street for Flamel Technologies SA. (BioWorld International)